Catalyst Pharmaceutical Partners, Inc. Enters Oversold Territory - Tale of the Tape


Shutterstock photo

Catalyst Pharmaceutical Partners, Inc.'s ( CPRX ) share price has entered into oversold territory with an RSI value of 25.81. The Zacks Consensus Estimate on Catalyst Pharmaceutical Partners, Inc.'s earnings for the full year period has loss of 0.01 cents over the past two months to $-0.25 per share. Currently, Catalyst Pharmaceutical Partners, Inc. is a Zacks #1 Rank ("Strong Buy"), suggesting that now might be a good time to get in on ( CPRX ) after its recent drop.

CATALYST PHARMA (CPRX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , Stocks

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by